LENZ Therapeutics, Inc. (LENZ) Form 8-K — May 11, 2026
LENZ Therapeutics, Inc. reported total revenue of $1.9 million for the first quarter of 2026, including $1.7 million in product sales from VIZZ®. The company filled approximately 46,000 paid prescriptions and engaged over 10,000 unique prescribing eye care professionals from launch through Q1 2026. The company is expanding its sales force from 88 to 117 territories, with the full deployment expected by the end of Q2 2026.
Key figures
- Eps Beat
- 0
- Revenue
- 1901
- Total Debt
- 26043
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 272535
- Cash Position
- 24772
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 31352702
- R&DExpenses
- 0
- SG&AExpenses
- 44960
- Daily Doses Sold
- 1200000
- Upfront Payment
- 250
- Prescriptions Filled
- 46000
- Prescribing Professionals
- 10000
Price after filing
1 day: -20.8%7 days: -30.9%30 days: -32.0%
Close on the filing date to close N calendar days later (from $9.99). Historical, not a forecast.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.